Lindbrook Capital LLC Purchases 75 Shares of Insulet Co. (NASDAQ:PODD)

Lindbrook Capital LLC grew its position in shares of Insulet Co. (NASDAQ:PODD) by 64.1% in the 4th quarter, HoldingsChannel reports. The fund owned 192 shares of the medical instruments supplier’s stock after buying an additional 75 shares during the period. Lindbrook Capital LLC’s holdings in Insulet were worth $42,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parkside Financial Bank & Trust increased its holdings in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares in the last quarter. Wolff Wiese Magana LLC increased its holdings in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Insulet during the third quarter valued at approximately $31,000. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in shares of Insulet during the fourth quarter valued at approximately $43,000.

Insider Activity

In other news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.90% of the company’s stock.

Insulet Stock Down 1.8 %

PODD stock opened at $164.17 on Friday. The stock’s fifty day simple moving average is $172.00 and its two-hundred day simple moving average is $179.25. The company has a current ratio of 3.51, a quick ratio of 2.62 and a debt-to-equity ratio of 1.86. Insulet Co. has a 1-year low of $125.82 and a 1-year high of $335.91. The stock has a market cap of $11.50 billion, a P/E ratio of 56.42, a P/E/G ratio of 3.01 and a beta of 0.98.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. During the same quarter in the previous year, the firm earned $0.55 earnings per share. The business’s revenue was up 37.9% on a year-over-year basis. Analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on PODD shares. Barclays decreased their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Piper Sandler decreased their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. upped their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Finally, Stifel Nicolaus upped their price target on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $243.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.